Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMAG PHARMACEUTICALS, INC.AMAG · Entity 145305 | President & COO | February 23, 2017 | February 27, 2017 |
| Larimar Therapeutics, Inc.LRMR · Entity 5634 | Director | May 19, 2026 | May 20, 2026 |
| Spero Therapeutics, Inc.SPRO · Entity 7014 | Director | June 23, 2026 | June 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMAG PHARMACEUTICALS, INC.
Report date February 23, 2017 · Filed February 27, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 138,195 |
Ending reported balance
After 2017-02-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-02-23 · Grant · Acquired 12,000 · Balance 126,195 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F2: These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Third Amended and Restated 2007 Equity Incentive Plan (as amended the "Plan") and will vest in three equal annual installments with the first installment vesting on February 23, 2018. F3: Not applicable. Row 2 · 2017-02-23 · Grant · Acquired 12,000 · Balance 138,195 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F4: These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending December 31, 2019, subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered pursuant to the award ("Target Award"); however, the amount that vests could range from zero to 150% of the Target Award. F3: Not applicable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.75 · Expires 2027-02-23 | Direct | 30,000 |
Reported balance
After 2017-02-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-02-23 · Grant · Acquired 30,000 · Balance 30,000 F3: Not applicable. F5: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer").
F2: These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Third Amended and Restated 2007 Equity Incentive Plan (as amended the "Plan") and will vest in three equal annual installments with the first installment vesting on February 23, 2018.
F3: Not applicable.
F4: These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending December 31, 2019, subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered pursuant to the award ("Target Award"); however, the amount that vests could range from zero to 150% of the Target Award.
F5: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter.
Larimar Therapeutics, Inc.
Report date May 19, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.33 · Expires 2036-05-19 | Direct | 55,150 |
Reported balance
After 2026-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 55,150 · Balance 55,150 F1: The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.
Spero Therapeutics, Inc.
Report date June 23, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 85,000 |
Reported balance
After 2026-06-23 transaction · row 1
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 10,000 · Balance 85,000 F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.15 · Expires 2036-06-23 | Direct | 20,000 |
Reported balance
After 2026-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-23 · Grant · Acquired 20,000 · Balance 20,000 F2: The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date.
F2: The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Orchard Therapeutics plc
Report date January 24, 2024 · Filed January 24, 2024
Section 16 reporting ended · disclosed 2024-01-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-01-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-01-24 · Disposition to issuer · Disposed 92,081 · Balance 0 F1: The ordinary shares, nominal value GBP per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares. F2: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2029-01-15 | Direct | 0 |
Reported balance
After 2024-01-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-24 · Disposition to issuer · Disposed 99,980 · Balance 0 F2: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023. F4: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a "Transition Award") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date. F1: The ordinary shares, nominal value GBP per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2030-01-01 | Direct | 0 |
Reported balance
After 2024-01-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-24 · Disposition to issuer · Disposed 199,990 · Balance 0 F2: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023. F4: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a "Transition Award") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date. F1: The ordinary shares, nominal value GBP per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2030-03-31 | Direct | 0 |
Reported balance
After 2024-01-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-24 · Disposition to issuer · Disposed 149,990 · Balance 0 F2: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023. F4: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a "Transition Award") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date. F1: The ordinary shares, nominal value GBP per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2031-01-31 | Direct | 0 |
Reported balance
After 2024-01-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-01-24 · Disposition to issuer · Disposed 309,990 · Balance 0 F2: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023. F4: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a "Transition Award") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date. F1: The ordinary shares, nominal value GBP per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2031-01-31 | Direct | 0 |
Reported balance
After 2024-01-24 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-01-24 · Disposition to issuer · Disposed 27,730 · Balance 0 F2: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023. F4: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a "Transition Award") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date. F1: The ordinary shares, nominal value GBP per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2032-05-31 | Direct | 0 |
Reported balance
After 2024-01-24 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-01-24 · Disposition to issuer · Disposed 335,000 · Balance 0 F2: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023. F4: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a "Transition Award") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date. F1: The ordinary shares, nominal value GBP per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2032-10-03 | Direct | 0 |
Reported balance
After 2024-01-24 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-01-24 · Disposition to issuer · Disposed 457,800 · Balance 0 F2: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023. F4: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a "Transition Award") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date. F1: The ordinary shares, nominal value GBP per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2032-10-03 | Direct | 0 |
Reported balance
After 2024-01-24 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-01-24 · Disposition to issuer · Disposed 75,000 · Balance 0 F2: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023. F4: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a "Transition Award") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date. F1: The ordinary shares, nominal value GBP per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2033-02-28 | Direct | 0 |
Reported balance
After 2024-01-24 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-01-24 · Disposition to issuer · Disposed 405,590 · Balance 0 F2: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023. F4: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a "Transition Award") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date. F1: The ordinary shares, nominal value GBP per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2033-02-28 | Direct | 0 |
Reported balance
After 2024-01-24 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-01-24 · Disposition to issuer · Disposed 179,390 · Balance 0 F2: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023. F4: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a "Transition Award") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date. F1: The ordinary shares, nominal value GBP per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares. |
Filing footnotes · ownership attribution and instrument terms
F1: The ordinary shares, nominal value GBP per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares.
F2: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC.
F3: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023.
F4: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a "Transition Award") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2021 Filed May 17, 2021 21:04 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (right to buy) · Derivative | 8,300 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001192482-21-000439 · edgar.xml · derivative · entry 1 THOMAS FRANK E · CIK 0001242616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,300 Underlying: Common Stock · 8,300 shares Expires 2031-05-12 F1 · derivative.exercise_date: The Option vests on the earlier of (a) May 12, 2022 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:00 UTC | Orchard Therapeutics plc ORTX · Entity 94933 | GrantStock Option (Right to Buy) · Derivative | 310,000 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001209191-21-007312 · doc4.xml · derivative · entry 2 THOMAS FRANK E · CIK 0001242616 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,000 Underlying: Ordinary Shares · 310,000 shares Expires 2031-01-31 F3 · derivative.exercise_date: The shares subject to this option vest in equal monthly installments over the four years after February 1, 2021. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:00 UTC | Orchard Therapeutics plc ORTX · Entity 94933 | GrantStock Option (Right to Buy) · Derivative | 27,731 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001209191-21-007312 · doc4.xml · derivative · entry 1 THOMAS FRANK E · CIK 0001242616 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,731 Underlying: Ordinary Shares · 27,731 shares Expires 2031-01-31 F1 · derivative.exercise_date: The shares subject to this option vest in 12 equal monthly installments commencing on February 1, 2021. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 21:15 UTC | Orchard Therapeutics plc ORTX · Entity 94933 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001209191-21-006430 · doc4.xml · derivative · entry 2 THOMAS FRANK E · CIK 0001242616 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,185 Underlying: Ordinary Shares · 10,000 shares Expires 2028-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 124,407 shares subject to this option vested on January 15, 2019 and the remaining shares vest in equal monthly installments over the three years thereafter. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 21:15 UTC | Orchard Therapeutics plc ORTX · Entity 94933 | Exercise / conversionOrdinary Shares | 10,000 | $2.44 | $24,400.00 |
DisclosureSEC source: 0001209191-21-006430 · doc4.xml · nonDerivative · entry 1 THOMAS FRANK E · CIK 0001242616 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 21:49 UTC | Orchard Therapeutics plc ORTX · Entity 94933 | Tax withholdingOrdinary Shares | 3,706 | $6.72 | $24,904.32 |
DisclosureSEC source: 0001209191-21-003254 · doc4.xml · nonDerivative · entry 2 THOMAS FRANK E · CIK 0001242616 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,081 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:49 UTC | Orchard Therapeutics plc ORTX · Entity 94933 | GrantOrdinary Shares | 10,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-003254 · doc4.xml · nonDerivative · entry 1 THOMAS FRANK E · CIK 0001242616 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,787 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: On January 16, 2019, the Reporting Person was granted certain performance-based Restricted Share Units ("RSUs"), the vesting of which was subject to the achievement of certain performance criteria. As of the transaction date, the first of three performance criteria was met, resulting in the vesting of 10,667 RSUs. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:28 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 1,314 | $13.31 Strike: $17.93 | $17,489.34 |
DisclosureSEC source: 0000899243-21-000691 · doc4.xml · derivative · entry 1 THOMAS FRANK E · CIK 0001242616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,314 Underlying: Common Stock · 1,314 shares Expires 2031-01-04 F2 · price: This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $17,500 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy. F1 · derivative.exercise_date: This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director. Read SEC document |
| October 27, 2020 Filed Oct 27, 2020 21:37 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $13.52 | $0.00 |
DisclosureSEC source: 0000899243-20-029337 · doc4.xml · derivative · entry 1 THOMAS FRANK E · CIK 0001242616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2030-10-27 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on October 27, 2021 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 17:52 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (right to buy) · Derivative | 16,600 | $0.00 Strike: $11.90 | $0.00 |
DisclosureSEC source: 0001192482-20-000738 · edgar.xml · derivative · entry 1 THOMAS FRANK E · CIK 0001242616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,600 Underlying: Common Stock · 16,600 shares Expires 2030-07-16 F1 · derivative.exercise_date: The Option was granted on July 16, 2020 subject to stockholder approval, which was obtained at the Company's special meeting of stockholders on September 29, 2020. The vesting commencement date for the option is July 16, 2020, and the option vests in equal monthly installments over 36 months, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:03 UTC | Orchard Therapeutics plc ORTX · Entity 94933 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001209191-20-036661 · doc4.xml · derivative · entry 2 THOMAS FRANK E · CIK 0001242616 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,185 Underlying: Ordinary Shares · 10,000 shares Expires 2028-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 124,407 shares subject to this option vested on January 15, 2019 and the remaining shares vest in equal monthly installments over the three years thereafter. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:03 UTC | Orchard Therapeutics plc ORTX · Entity 94933 | Exercise / conversionOrdinary Shares | 10,000 | $2.44 | $24,400.00 |
DisclosureSEC source: 0001209191-20-036661 · doc4.xml · nonDerivative · entry 1 THOMAS FRANK E · CIK 0001242616 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:26 UTC | Orchard Therapeutics plc ORTX · Entity 94933 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $7.05 | $0.00 |
DisclosureSEC source: 0001209191-20-023123 · doc4.xml · derivative · entry 1 THOMAS FRANK E · CIK 0001242616 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Ordinary Shares · 150,000 shares Expires 2030-03-31 F1 · derivative.exercise_date: The shares subject to this option vest in equal monthly installments over the four years after April 1, 2020. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 00:09 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 2,704 | $6.47 Strike: $9.87 | $17,494.88 |
DisclosureSEC source: 0000899243-20-000631 · doc4.xml · derivative · entry 1 THOMAS FRANK E · CIK 0001242616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,704 Underlying: Common Stock · 2,704 shares Expires 2030-01-02 F2 · price: This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $17,500 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy. F1 · derivative.exercise_date: This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:24 UTC | Orchard Therapeutics plc ORTX · Entity 94933 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $13.58 | $0.00 |
DisclosureSEC source: 0001209191-20-001811 · doc4.xml · derivative · entry 1 THOMAS FRANK E · CIK 0001242616 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Ordinary Shares · 200,000 shares Expires 2030-01-01 F1 · derivative.exercise_date: The shares subject to this option vest in equal monthly installments over the four years after January 2, 2020. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 26, 2019 Filed Jun 27, 2019 23:36 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0000899243-19-018480 · doc4.xml · derivative · entry 1 THOMAS FRANK E · CIK 0001242616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2029-06-26 F1 · derivative.exercise_date: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 26, 2020 or the date of the 2020 annual meeting of stockholders, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company. Read SEC document |
| June 05, 2019 Filed Jun 5, 2019 22:50 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 6,073 | $0.00 Strike: $10.67 | $0.00 |
DisclosureSEC source: 0000899243-19-015668 · doc4.xml · derivative · entry 1 THOMAS FRANK E · CIK 0001242616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires 2029-06-05 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 5, 2020 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 21:44 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.79 | $0.00 |
DisclosureSEC source: 0000899243-18-015560 · doc4.xml · derivative · entry 1 THOMAS FRANK E · CIK 0001242616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 6, 2019 or the date of the 2019 annual meeting of stockholders, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 00:02 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 6,073 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0000899243-18-015330 · doc4.xml · derivative · entry 1 THOMAS FRANK E · CIK 0001242616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires 2028-06-05 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 5, 2019, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:09 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0000899243-17-017076 · doc4.xml · derivative · entry 1 THOMAS FRANK E · CIK 0001242616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2027-06-21 F1 · derivative.exercise_date: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 21, 2018 or the date of the 2018 annual meeting of stockholders, subject to the director's continued service on the board of directors. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 19:01 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $23.75 | Not disclosed |
DisclosureSEC source: 0001179110-17-003322 · edgar.xml · derivative · entry 3 THOMAS FRANK E · CIK 0001242616 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-02-23 F3 · price: Not applicable. F5 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 19:01 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 12,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-003322 · edgar.xml · nonDerivative · entry 2 THOMAS FRANK E · CIK 0001242616 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,195 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F4 · shares: These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending December 31, 2019, subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered pursuant to the award ("Target Award"); however, the amount that vests could range from zero to 150% of the Target Award. F3 · price: Not applicable. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 19:01 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 12,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-003322 · edgar.xml · nonDerivative · entry 1 THOMAS FRANK E · CIK 0001242616 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,195 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F2 · shares: These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Third Amended and Restated 2007 Equity Incentive Plan (as amended the "Plan") and will vest in three equal annual installments with the first installment vesting on February 23, 2018. F3 · price: Not applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.